Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
21.8%/yr
±5.2% · revenue growth to justify current price
FCF-Based Reverse DCF
18.4%/yr
±3.2% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockEdwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
Edwards delivered solid FY2025 with 11.5% revenue growth driven by TMTT (+56%) while TAVR matures (+9%). Strong balance sheet with $4.2B cash, $1.6B OCF. Key concerns: litigation expenses surged to $3...